Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Cassandra Rayer (1) , Maria Nachury (2) , Arnaud Bourreille (3) , Xavier Roblin (4) , Laurent Peyrin-Biroulet (5, 6) , Stephanie Viennot (7) , Mathurin Flamant (8) , David Laharie (9) , Bénédicte Caron (5, 6) , Marie Dewitte (10, 1) , Laurent Siproudhis (1, 10) , Mathurin Fumery (11, 12) , Guillaume Bouguen (13, 1, 10)

1 CHU Pontchaillou [Rennes]
2 INFINITE (Ex-Liric) - Institute for Translational Research in Inflammation - U 1286
3 CHU Nantes - Centre hospitalier universitaire de Nantes
4 Service de gastroentérologie [CHU Saint-Etienne]
5 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
6 Service d'Hépato-gastro-entérologie [CHRU Nancy]
7 CHU Caen
8 Clinique Jules-Vernes [Nantes]
9 CHU Bordeaux [Bordeaux]
10 CIC - Centre d'Investigation Clinique [Rennes]
11 PERITOX - Périnatalité et Risques Toxiques - UMR INERIS_I 1
12 CHU Amiens-Picardie
13 NuMeCan - Nutrition, Métabolismes et Cancer

Domaines: Sciences du Vivant [q-bio]; Médecine humaine et pathologie

Cassandra Rayer, Maria Nachury, Arnaud Bourreille, Xavier Roblin, Laurent Peyrin-Biroulet, et al.. Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study. BMC Gastroenterology, 2023, 23 (1), pp.31. ⟨10.1186/s12876-022-02636-9⟩. ⟨hal-03980994⟩